CN104428001A - Raf抑制剂和mek抑制剂在黑素瘤治疗中的投与 - Google Patents

Raf抑制剂和mek抑制剂在黑素瘤治疗中的投与 Download PDF

Info

Publication number
CN104428001A
CN104428001A CN201380018595.7A CN201380018595A CN104428001A CN 104428001 A CN104428001 A CN 104428001A CN 201380018595 A CN201380018595 A CN 201380018595A CN 104428001 A CN104428001 A CN 104428001A
Authority
CN
China
Prior art keywords
tak
melanoma
inhibitor
use according
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380018595.7A
Other languages
English (en)
Chinese (zh)
Inventor
有田健雄
土屋俊太郎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CN104428001A publication Critical patent/CN104428001A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380018595.7A 2012-03-30 2013-03-29 Raf抑制剂和mek抑制剂在黑素瘤治疗中的投与 Pending CN104428001A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261618006P 2012-03-30 2012-03-30
US61/618,006 2012-03-30
PCT/IB2013/052556 WO2013144923A1 (en) 2012-03-30 2013-03-29 Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma

Publications (1)

Publication Number Publication Date
CN104428001A true CN104428001A (zh) 2015-03-18

Family

ID=48326371

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380018595.7A Pending CN104428001A (zh) 2012-03-30 2013-03-29 Raf抑制剂和mek抑制剂在黑素瘤治疗中的投与

Country Status (6)

Country Link
US (1) US20150126533A1 (cg-RX-API-DMAC10.html)
EP (1) EP2830664A1 (cg-RX-API-DMAC10.html)
JP (1) JP2015511632A (cg-RX-API-DMAC10.html)
CN (1) CN104428001A (cg-RX-API-DMAC10.html)
CA (1) CA2868954A1 (cg-RX-API-DMAC10.html)
WO (1) WO2013144923A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117177754A (zh) * 2021-02-19 2023-12-05 首日生物制药公司 Raf抑制剂和mek抑制剂的组合

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY192088A (en) 2013-11-11 2022-07-26 Amgen Inc Combinantion therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
UY36046A (es) * 2014-03-26 2015-10-30 Millennium Pharm Inc Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
US20190117652A1 (en) * 2014-12-23 2019-04-25 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and taxanes
EP3236948A4 (en) * 2014-12-23 2018-10-03 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
WO2017066664A1 (en) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Combination therapy including a raf inhibitor for the treatment of colorectal cancer
WO2017165491A1 (en) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer
WO2019139970A1 (en) * 2018-01-09 2019-07-18 Duke University Topical administration of mek inhibiting agents for the treatment of skin disorders
EP4065122A4 (en) * 2019-11-27 2023-12-27 Day One Biopharmaceuticals, Inc. SOLID DISPERSION OF PAN-RAF KINASE INHIBITOR
CN117042772A (zh) * 2020-11-06 2023-11-10 首日生物制药公司 用于治疗低级别胶质瘤的raf抑制剂
AU2021376286A1 (en) * 2020-11-06 2023-06-22 Dana-Farber Cancer Institute, Inc. Raf inhibitor for treating low grade glioma
CA3211167A1 (en) * 2021-02-19 2022-08-25 Samuel C. BLACKMAN Combination of raf inhibitor and mek inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079814A2 (en) * 2006-12-20 2008-07-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
WO2009006389A2 (en) * 2007-06-29 2009-01-08 Sunesis Pharmaceuticals, Inc. Pyrimidine derivatives useful as raf kinase inhibitors
WO2010064722A1 (en) * 2008-12-02 2010-06-10 Takeda Pharmaceutical Company Limited Benzothiazole derivatives as anticancer agents
WO2011047238A1 (en) * 2009-10-16 2011-04-21 Glaxosmithkline Llc Combination

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008120004A1 (en) * 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
WO2012145503A1 (en) * 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079814A2 (en) * 2006-12-20 2008-07-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
WO2009006389A2 (en) * 2007-06-29 2009-01-08 Sunesis Pharmaceuticals, Inc. Pyrimidine derivatives useful as raf kinase inhibitors
WO2010064722A1 (en) * 2008-12-02 2010-06-10 Takeda Pharmaceutical Company Limited Benzothiazole derivatives as anticancer agents
WO2011047238A1 (en) * 2009-10-16 2011-04-21 Glaxosmithkline Llc Combination

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117177754A (zh) * 2021-02-19 2023-12-05 首日生物制药公司 Raf抑制剂和mek抑制剂的组合

Also Published As

Publication number Publication date
JP2015511632A (ja) 2015-04-20
WO2013144923A1 (en) 2013-10-03
US20150126533A1 (en) 2015-05-07
CA2868954A1 (en) 2013-10-03
EP2830664A1 (en) 2015-02-04

Similar Documents

Publication Publication Date Title
CN104245699B (zh) Nedd8‑活化酶抑制剂和低甲基化剂的投与
JP2015511632A (ja) メラノーマの治療におけるｒａｆ阻害剤およびｍｅｋ阻害剤の投与
KR20110028651A (ko) (ａ) 포스포이노시타이드 3-키나제 억제제 및 (ｂ) ｒａｓ/ｒａｆ/ｍｅｋ 경로의 조절제의 조합물
US20160287605A1 (en) Combination therapy
JP2017214387A (ja) 増殖性疾患の治療のためのｈｓｐ９０阻害剤と組み合わせた２−カルボキサミドシクロアミノウレア誘導体
JP2002504511A (ja) 癌処置のためのエポチロンの使用
AU2010247397B2 (en) Combination of a phosphoinositide 3-kinase inhibitor and an antidiabetic compound
JP2018090566A (ja) 非小細胞肺癌の治療のためのｅｇｆｒ ｔ７９０ｍ阻害剤およびｃｄｋ阻害剤の組合せ
CN105050623A (zh) Pi3k抑制剂和c-met抑制剂的组合
MX2015004162A (es) Usos novedosos.
WO2020062951A1 (zh) 化合物及其用途
JP2014530181A (ja) ＰＩ３Ｋβ阻害剤ならびにＭＥＫおよびＲＡＦ阻害剤を含むＭＡＰＫ経路阻害剤を使用する、癌を処置するための組成物および方法
JP7640033B2 (ja) ピリド［１，２－ａ］ピリミジノン類似体の使用
JP2022533100A (ja) Ｎｏｔｃｈ活性化乳がんを治療するためのビスフルオロアルキル－１，４－ベンゾジアゼピノン化合物
TW202045180A (zh) 治療纖維化之方法
TW202337469A (zh) 治療小細胞肺癌之方法
JP2019112461A (ja) Ｎｅｄｄ８活性化酵素阻害剤及び化学療法剤の投与
JP2019508460A (ja) 増殖性疾病の組み合せ療法
JP2025508548A (ja) 淡明細胞型腎細胞癌の治療
US20240075041A1 (en) Treatment of eosinophilic disorders with avapritinib
KR20230061527A (ko) 염증성 장 질환을 치료하는 방법
JP2020519581A (ja) 肥満細胞疾患の処置のための方法及び医薬組成物
EA052412B1 (ru) Комбинированная терапия для лечения мастоцитоза
TW201315471A (zh) 使用ＰＩ３Ｋβ抑制劑及包括ＭＥＫ及ＲＡＦ抑制劑之ＭＡＰＫ通道抑制劑之供治療癌症之組合物及方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150318